Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAT Receptor Occupancy With OROS and IR Methylphenidate
NCT00302367Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2004
- Primary completion
- Apr 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of methylphenidate in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Dopamine Transporter Receptor Occupancy and d and l ritalinic acid and methylphenidate levels. Started Jan 2004; status: completed.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00302367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00302367.